Siglec-1 and -2 as potential biomarkers in autoimmune disease.
Proteomics Clin Appl
; 10(6): 635-44, 2016 06.
Article
em En
| MEDLINE
| ID: mdl-26752092
ABSTRACT
Autoimmune diseases (ADs) are currently treated with anti-inflammatory and immunosuppressive drugs, aimed at reducing symptoms of disease in order to improve quality of life for patients. However, for a significant number of patients these therapies are ineffective, leading to an increased risk of irreversible damage and eventual disability in certain cases. Growing evidence has implicated glycosylated proteins and their cognate receptors in modulation of the autoimmune response. This review will summarize these findings with particular focus on sialic acid-binding immunoglobulin-like lectin (Siglec)-1 and Siglec-2 involvement in AD. Fluctuations in these glycosylation-dependent pathways could act as sentinels of disease activity or drug responses. If validated, protein modification and cellular response markers could help clinicians achieve remission earlier.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Subpopulações de Linfócitos T
/
Lectina 2 Semelhante a Ig de Ligação ao Ácido Siálico
/
Receptores para Leptina
/
Lectina 1 Semelhante a Ig de Ligação ao Ácido Siálico
Limite:
Animals
/
Humans
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article